PRLD – prelude therapeutics incorporated (US:NASDAQ)
Stock Stats
News
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting [Yahoo! Finance]
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
Prelude Therapeutics (PRLD) had its price target raised by Citizens Jmp from $3.00 to $6.00. They now have a "market outperform" rating on the stock.
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 [Yahoo! Finance]
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
Form 3 Prelude Therapeutics For: Mar 05 Filed by: Brusky Sean P.
Form 8-K Prelude Therapeutics For: Mar 12
Form 424B5 Prelude Therapeutics
Form S-8 Prelude Therapeutics
Form 10-K Prelude Therapeutics For: Dec 31
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.